Cargando…

Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial

Background: Patient-reported outcomes (PROs), including health-related quality of life, are recommended to be routinely collected in clinical trials, but data are limited from trials of sarcoma patients. In this analysis, pooled PRO data are reported from patients with advanced or metastatic soft ti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Tine, Brian A, Krarup-Hansen, Anders, Hess, Lisa M, Abdul Razak, Albiruni R, Soldatenkova, Victoria, Wright, Jennifer, Park, Se Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081717/ https://www.ncbi.nlm.nih.gov/pubmed/35547106 http://dx.doi.org/10.1177/20363613221100033

Ejemplares similares

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas
por: Vitfell-Rasmussen, Joanna, et al.
Publicado: (2016)

Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study
por: Angarita, Fernando A., et al.
Publicado: (2016)

A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)
por: Veitch, Zachary, et al.
Publicado: (2019)

Clinical outcomes of non‐osteogenic, non‐Ewing soft‐tissue sarcoma of bone––experience of the Toronto Sarcoma Program
por: Veitch, Zachary W., et al.
Publicado: (2020)

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
por: Zuluaga-Sanchez, Santiago, et al.
Publicado: (2018)

Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck
por: Hahn, Ezra, et al.
Publicado: (2018)

Patient and Tumour Characteristics of Adult Head and Neck Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis
por: Andersen, Sakshi, et al.
Publicado: (2019)

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
por: Nguyen, James, et al.
Publicado: (2023)

Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas
por: Liffers, Sven-T, et al.
Publicado: (2013)

High cumulative doxorubicin dose for advanced soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Phase III Soft Tissue Sarcoma Trials: Success or Failure?
por: Lee, Alexander T. J., et al.
Publicado: (2017)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter
por: Dang, Jing-Yi, et al.
Publicado: (2022)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma
por: Yonemori, Kan, et al.
Publicado: (2018)

Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin
por: Kirilin, Evgeny M., et al.
Publicado: (2022)

Neoadjuvant and adjuvant doxorubicin chemotherapy in a case of feline soft tissue sarcoma
por: Torrigiani, Filippo, et al.
Publicado: (2019)

Type III collagen metabolism in soft tissue sarcomas.
por: Wiklund, T. A., et al.
Publicado: (1992)

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
por: Gong, Jun, et al.
Publicado: (2018)

Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
por: Gennatas, Spyridon, et al.
Publicado: (2020)

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin
por: Tsuchihashi, Kenji, et al.
Publicado: (2020)

Editorial: New therapeutics for soft tissue sarcomas
por: Weetall, Marla, et al.
Publicado: (2023)

A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas
por: Trucco, Matteo M., et al.
Publicado: (2018)

Immune checkpoint inhibitor resistance in soft tissue sarcoma
por: Eulo, Vanessa, et al.
Publicado: (2022)

Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma
por: Villalobos, Victor M., et al.
Publicado: (2019)

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
por: Nielsen, O. S., et al.
Publicado: (1998)

Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
por: Tian, Zhichao, et al.
Publicado: (2022)

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas: a systematic review and meta-analysis
por: Dang, Jingyi, et al.
Publicado: (2021)

Similar additive effects of doxorubicin in combination with photon or proton irradiation in soft tissue sarcoma models
por: Bernardo, Teresa, et al.
Publicado: (2023)

Evaluation of the accuracy of algorithms to identify soft tissue sarcoma (STS) in administrative claims
por: Princic, Nicole, et al.
Publicado: (2020)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide
por: Chawla, Sant P, et al.
Publicado: (2013)

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience
por: Striefler, Jana Käthe, et al.
Publicado: (2020)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

ATYPICAL PRESENTATION OF SOFT TISSUE SARCOMA
por: Rizzo, Victoria, et al.
Publicado: (2017)

Cardiac events among patients with sarcoma treated with doxorubicin by method of infusion: A real‐world database study
por: Cranmer, Lee D., et al.
Publicado: (2022)

Novel-fosfamide monotherapy or in combination with doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcoma: A pooled analysis of randomized clinical trials
por: Liu, Xin-Xiu, et al.
Publicado: (2023)

Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study
por: López-Pousa, A, et al.
Publicado: (2006)

Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS)
por: López-Pousa, A., et al.
Publicado: (2006)

Sequential Dose-Dense Doxorubicin and Ifosfamide in Advanced Soft-Tissue Sarcoma Patients in an Out-Patient-Basis Schedule
por: Almeida, G. F. G., et al.
Publicado: (2011)

Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas
por: Villar, Victor Hugo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6qvmh1u3lm4ulp2f4kiodjvj7r